Paper · 42952609
Disruption of ACTG1 potentiates anti-TIM-3 immunotherapy by reprogramming the immunosuppressive microenvironment via the CSF3/CSF3R axis in pancreatic cancer.
Zhu L and 16 others. Front Immunol, 2026.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Disruption of ACTG1 potentiates anti-TIM-3 immunotherapy by reprogramming the immunosuppressive microenvironment via the CSF3/CSF3R axis in pancreatic cancer. Papers, record 42952609. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42952609
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Disruption of ACTG1 potentiates anti-TIM-3 immunotherapy by reprogramming the immunosuppressive microenvironment via the CSF3/CSF3R axis in pancreatic cancer.
- Journal
- Front Immunol
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-30
Source PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Tumor Microenvironment | Major topic |
| Pancreatic Neoplasms | Major topic |
| Hepatitis A Virus Cellular Receptor 2 | Major topic |
| Carcinoma, Pancreatic Ductal | Major topic |
| Humans | |
| Animals | |
| Immunotherapy | |
| Cell Line, Tumor | |
| Signal Transduction | |
| Mice | |
| Prognosis | |
| Gene Expression Regulation, Neoplastic |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34,547,082 | Pancreatic Cancer: A Review. | JAMA | 2021 | https://conductscience.org/library/papers/34547082 | PubMed |
| 2 | 38,389,420 | The Regulatory Mechanism of Hypoxia-inducible Factor 1 and its Clinical Significance. | Curr Mol Pharmacol | 2024 | https://conductscience.org/library/papers/38389420 | PubMed |
| 3 | 27,757,304 | Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis. | Oncoimmunology | 2016 | https://conductscience.org/library/papers/27757304 | PubMed |
| 4 | 36,652,552 | NFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells. | Cancer Res | 2023 | https://conductscience.org/library/papers/36652552 | PubMed |
| 5 | 37,368,839 | Bioinformatic identification and experiment validation revealed that ACTG1 is a promising prognostic signature and therapeutic target for sepsis. | J Leukoc Biol | 2023 | https://conductscience.org/library/papers/37368839 | PubMed |
| 6 | 31,156,687 | Plants Grown in Parafilm-Wrapped Petri Dishes Are Stressed and Possess Altered Gene Expression Profile. | Front Plant Sci | 2019 | https://conductscience.org/library/papers/31156687 | PubMed |
| 7 | 40,166,931 | Targeting lactylation and the STAT3/CCL2 axis to overcome immunotherapy resistance in pancreatic ductal adenocarcinoma. | J Clin Invest | 2025 | https://conductscience.org/library/papers/40166931 | PubMed |
| 8 | 36,202,978 | AZIN1 RNA editing alters protein interactions, leading to nuclear translocation and worse outcomes in prostate cancer. | Exp Mol Med | 2022 | https://conductscience.org/library/papers/36202978 | PubMed |
| 9 | 38,702,773 | Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications. | Mol Cancer | 2024 | https://conductscience.org/library/papers/38702773 | PubMed |
| 10 | 34,856,725 | Actin gamma 1 is a critical regulator of pancreatic ductal adenocarcinoma. | Saudi J Gastroenterol | 2022 | https://conductscience.org/library/papers/34856725 | PubMed |
1 to 10 of 49
See all 49 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first.
None in this release.
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42952609
GET https://conductscience.org/api/papers/v1/42952609/references?page=2